Clinical Trial Update: Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients

View source ↗

Summary

A completed registry study monitored the susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients to aztreonam.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Cayston (aztreonam for inhalation) (aztreonam)

Snippet

Sponsor: Gilead Sciences | Conditions: Cystic Fibrosis | Status: COMPLETED